Scientific Poster: Development of Relative Potency Assay for ADC Using Multiple Kinetic Assays Before Finalizing Endpoint Readout

Discover a comprehensive strategy for evaluating the potency of antibody-drug conjugates (ADCs).

Led by Associate Director of Analytical Methods Development, Alena Nikolskaya, our approach integrates three critical components—real-time apoptosis tracking, secondary necrosis measurement, and a final, optimized viability read—into one cohesive workflow.

By combining luminescent Annexin V (to monitor early apoptotic events) with fluorescent DNA-binding assays (to detect membrane-compromised cells) and culminating in a CellTiter-Glo® endpoint, this method provides a more thorough view of ADC-induced cytotoxicity than traditional endpoint-only assays.

Key Highlights

• Multiple Kinetic Readouts: Track apoptosis onset and progression to necrosis in real time, capturing nuanced effects of ADC treatment.
• Enhanced Precision: Optimize parameters such as cell density and dose response to reveal subtle potency differences.
• Streamlined Workflow: Real-time measurements do not interfere with the final viability assessment, ensuring reliable endpoint data.
• Improved Assay Sensitivity: Leverage both luminescent and fluorescent signals to confidently distinguish ADC-driven apoptotic events from other cytotoxic mechanisms.

This multi-step methodology delivers a more robust, informative assessment of ADC relative potency and pinpoints the ideal time window for endpoint readouts. To learn how these insights can accelerate your ADC development, connect with our experts at Abzena.

Download Poster